Article info

other Versions

PDF
Randomised controlled trial
Semaglutide is non-inferior to placebo for cardiovascular outcomes in patients with type 2 diabetes

Authors

  1. Correspondence to: Dr Denise Campbell-Scherer, Alberta Diabetes Institute, Clinical Research Unit, 2-004 Li Ka Shing Ctr, 87 Ave and 112st, Edmonton, Alberta T6G 2E1, Canada; denise.campbell-scherer{at}ualberta.ca
View Full Text

Citation

Campbell-Scherer D
Semaglutide is non-inferior to placebo for cardiovascular outcomes in patients with type 2 diabetes

Publication history

  • Published online 7 March 2017.

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.